comparemela.com

Page 14 - J Public Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chronic Overlapping Pain Conditions and Long-term Opioid Treatment

Little is known about opioid prescribing patterns in patients with chronic overlapping pain conditions. This study suggests target populations for interventions to manage chronic pain.

United statesOregon state universityAustj genLe rescheFlorh comorbidMaria ukhanovaCommonwealth fundOutcomes research instituteNational association of community health centersDepartment of family medicineNational institutes of healthHealth serv resDepartment of public healthCollege of pharmacyUs veterans health administrationResearch data warehouse

Association Between Low-Income Subsidies and Inequities in Orally Administered Antimyeloma Therapy Use

Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.

New yorkUnited statesKyle cookShelleya jazowskiAnn pharmacotherLatinx whiteStrategic initiative of university north carolinaNational academiesNational academy for state healthMedicare payment advisory commissionHealth serv resSchool of medicineDepartment of population health sciencesInstitute for clinicalJ public healthUniversity of north carolina at chapel hill

Astellas VEOZAH™ (fezolinetant) Approved by U S FDA for Treatment of Vasomotor Symptoms Due to Menopause

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).

United statesAstellas pharmaNaoki okamuraGenevieve neal perryDrug administrationJ public healthAstellas pharma incAstellas incHead of biopharma developmentSchool of medicine department obstetricsPrnewswire astellas pharma incHealth qual life outcomesFull interactive multimediaMedicine departmentMarci englishVice president

Astellas VEOZAH™ (fezolinetant) Approved by U S FDA for Treatment of Vasomotor Symptoms Due to Menopause

VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause TOKYO, May 12, 2023 /PRNewswire/ Astellas Pharma Inc. today. | June 14, 2023

United statesGenevieve neal perryNaoki okamuraAstellas pharmaPrnewswire astellas pharma incHealth qual life outcomesSchool of medicine department obstetricsAstellas pharma incJ public healthDrug administrationAstellas incHead of biopharma developmentFull interactive multimediaMedicine departmentMarci englishVice president

Pharmacists Are in Key Positions to Tackle Black Maternal Mortality Disparities

Tackling racial disparities among health care providers can help improve disparities faced by patients.

United statesDavidr williamHealth serv resIts influence on health care outcomesInstitute of medicineAssociation of american medical collegesJ public healthCenters for diseasePublic healthEveryday discriminationSafety officersAmerican medicalMortality ratesSevere maternal morbidityClinical obstetricsDisease control

vimarsana © 2020. All Rights Reserved.